inv-01: Initial bariatric surgery medical necessity — RYGB, LASGB, sleeve gastrectomy, BPD/DS, SADI-S, SIPS
Initial bariatric surgery (RYGB, LASGB, sleeve gastrectomy, BPD/DS, SADI‑S, SIPS) is considered medically necessary when ALL of the following selection criteria are met:
ALL of the following
Member is an adult (age ≥ 18 years) or an adolescent who has completed skeletal growth (generally ≥13 years for girls, ≥15 years for boys).
Persistent severe obesity documented in contemporaneous clinical records, defined as either: BMI > 40 kg/m2 (or > 37.5 kg/m2 for persons of Asian ancestry), OR BMI > 35 kg/m2 (or > 32.5 kg/m2 for persons of Asian ancestry) with at least one of the following severe comorbidities: clinically significant obstructive sleep apnea, coronary heart disease with objective documentation, medically refractory hypertension (BP >140/90 mmHg despite ≥3 antihypertensive agents of different classes), type 2 diabetes mellitus, or nonalcoholic steatohepatitis (NASH) confirmed by biopsy or advanced fibrosis by noninvasive testing.
Member has attempted weight loss previously without successful long-term weight reduction and has participated in an intensive multicomponent behavioral intervention documented in the medical record (program with ≥12 sessions on separate dates within 2 years prior to surgery; may be group or individual, in-person or remote, and includes nutrition, physical activity, and behavioral modification components).
Screening for obstructive sleep apnea using a validated tool (e.g., ESS, STOP, STOP‑Bang, Berlin, Wisconsin Sleep Questionnaire, MVAP). Documentation that screening was performed must be in the medical record (screening not required if member already has a diagnosis of OSA).
inv-02: Vertical banded gastroplasty (VBG) — Covered when ALL criteria are met
Vertical banded gastroplasty (VBG) is considered medically necessary only when ALL of the following are met:
ALL of the following
Member meets the general selection criteria for obesity surgery (see Initial bariatric surgery criteria).
Member is at increased risk of adverse consequences from RYGB due to the presence of any of the following: demonstrated extensive intestinal adhesions from prior major abdominal surgery or trauma, hepatic cirrhosis with elevated liver function tests, inflammatory bowel disease (Crohn's disease or ulcerative colitis), poorly controlled systemic disease (ASA Class IV), or radiation enteritis.
inv-03: Management of bariatric surgery complications — medically necessary items listed
Management of bariatric surgery complications — the following interventions are considered medically necessary:
ANY of the following
Removal of a gastric band when recommended by the treating physician (e.g., band erosion, infection, irreparable malfunction).
Surgery to correct complications from bariatric surgery such as obstruction, stricture, erosion, or band slippage when clinically indicated and documented.
Surgery for symptomatic 'candy cane' (Roux) syndrome when diagnosis is confirmed by endoscopy or upper GI contrast studies and member has compatible symptoms (abdominal pain, nausea, emesis).
Replacement of an adjustable band when there are complications (e.g., port leakage, irreparable slippage) that cannot be corrected with band manipulation or adjustments.
inv-04: Experimental and investigational procedures — list of not covered procedures and devices
The following procedures, devices, and techniques are considered experimental and investigational (not covered) due to insufficient evidence of safety or effectiveness:
ANY of the following
Adjunctive omentectomy performed solely to improve metabolic outcomes.
AspireAssist aspiration therapy except where FDA‑approved indications apply and criteria met; 'Band over bypass' (placement of LASGB over prior RYGB) and 'band over sleeve' (LASGB over sleeve gastrectomy).
Bariatric surgery performed solely to treat idiopathic intracranial hypertension or infertility in persons not meeting standard medical necessity criteria for obesity surgery.
Bariatric surgery for treatment of type 2 diabetes in persons with BMI < 35 kg/m2 (except when meeting updated specialty guidelines and payer‑specific diabetes surgery criteria if present).
inv-05: Related routine procedures — routine procedures related to bariatric surgery
Related routine procedures associated with bariatric surgery:
ANY of the following
Routine cholecystectomy performed in concert with elective bariatric procedures is considered medically necessary given high incidence of gallbladder disease after bariatric surgery.
Routine liver biopsy during bariatric surgery is considered not medically necessary in the absence of signs or symptoms of liver disease (e.g., elevated liver enzymes, hepatomegaly, imaging suggesting cirrhosis). Biopsy may be indicated selectively for suspected cirrhosis or when noninvasive testing suggests advanced fibrosis/NASH.
inv-06: Surgical candidacy and preoperative requirements — Covered when ALL of the following are met
Surgical candidacy and preoperative requirements — candidate meets coverage when ALL of the following are met:
ALL of the following
Meets BMI and comorbidity thresholds as described in initial bariatric surgery criteria (BMI criteria, comorbidity documentation).
Documentation of prior attempts at non‑surgical weight loss and participation in an intensive multicomponent behavioral intervention (program documentation, ≥12 sessions within 2 years, or program records substituting for medical records).
Preoperative evaluation including screening for OSA (or documented diagnosis), appropriate medical clearance, and assessment for perioperative risk (ASA classification).
Preoperative nutritional assessment and plan, including assessment for micronutrient deficiencies and counseling by registered dietitian when indicated; plan for lifelong supplementation and follow‑up as appropriate.
inv-07: Adolescent candidate criteria (expert panel) — adolescent and pediatric recommendations
Adolescent candidate recommendations (expert panel) —
ALL of the following
Bariatric surgery may be considered for adolescents who have completed bone growth (typically ≥13 years for girls and ≥15 years for boys).
Candidates should have severe obesity (BMI ≥40) with severe comorbidities or super‑obesity (BMI ≥50) with comorbidities that may be remedied by weight loss, and should have failed organized weight‑loss attempts (generally ≥6 months).
Referral should be to centers with multidisciplinary pediatric/adolescent weight management teams experienced in the unique needs of adolescents, with capacity to collect long‑term outcomes and provide comprehensive perioperative and long‑term follow‑up.
inv-08: Preoperative documentation and psychological evaluation — requirements for evaluation
Preoperative documentation and psychological evaluation requirements:
ALL of the following
Medical records must document the patient's participation and compliance with an intensive multicomponent behavioral intervention (program name, dates, attendance, progress). Program records from recognized commercial programs (e.g., Weight Watchers, Jenny Craig, OptiFast) may substitute when available.
Physician documentation of preoperative assessment, prescribed interventions, and progress toward weight‑loss goals (including counseling on diet, physical activity, and behavioral strategies).
Comprehensive psychological evaluation by a licensed psychologist or psychiatrist is required for candidates with history of severe psychiatric disturbance, active substance abuse, or other psychosocial factors that may impair informed consent or postoperative compliance.
inv-09: Liver biopsy / NAFLD considerations — liver assessment for bariatric candidates
Liver assessment and biopsy considerations for bariatric candidates:
ANY of the following
Routine liver biopsy at the time of bariatric surgery is not medically necessary in the absence of clinical or laboratory signs of liver disease. Selective biopsy may be indicated when suspected cirrhosis, unexplained hepatic abnormalities, or noninvasive testing (FibroScan, FibroTest/ActiTest, MRE, ELF) suggests advanced fibrosis or NASH.
Noninvasive tests (FIB‑4, NAFLD Fibrosis Score, transient elastography [FibroScan], magnetic resonance elastography) can be used as first‑line tools to identify advanced fibrosis; TE and MRE are useful at referral centers to select patients for biopsy.
inv-10: Procedure efficacy and safety summaries — procedure-specific summaries and comparative effectiveness/safety notes
Procedure‑specific efficacy and safety summaries — evidence and professional positions:
ANY of the following
RYGB: Considered the procedure of choice in many settings due to durable weight loss and comorbidity resolution; long‑limb RYGB may be used for super‑obese patients. Associated risks include nutritional deficiencies (iron, B12, calcium) and potential for anastomotic complications; laparoscopic approach has lower mortality and faster recovery but differing complication profiles compared with open surgery.
Sleeve gastrectomy: Increasingly used; evidence shows substantial short‑ to mid‑term weight loss. Considered an approved bariatric procedure by ASMBS though long‑term data are limited. May be used as first‑stage procedure for high‑risk/super‑obese patients; conversion to RYGB is a treatment option for refractory GERD when criteria are met.
LASGB (adjustable gastric band): Minimally invasive and adjustable, but associated with lower long‑term weight loss than RYGB and high reoperation/band‑removal rates; may be appropriate in selected patients and for salvage after prior RYGB in select circumstances but carries substantial revision risk.
inv-11: Sleeve gastrectomy: evidence and professional position
Sleeve gastrectomy — evidence summary and professional position:
ANY of the following
Systematic reviews and some randomized and observational studies show sleeve gastrectomy produces substantial short‑term weight loss and comorbidity improvements; evidence suggests greater weight loss than LASGB and similar short‑term weight loss compared with RYGB in limited trials, but long‑term comparative data are limited.
ASMBS considers sleeve gastrectomy an approved bariatric procedure, particularly useful as a first‑stage operation in high‑risk or super‑obese patients; professional organizations emphasize need for long‑term outcome data and monitoring for complications such as leaks, strictures, and reflux.
inv-12: Loop and mini gastric bypass — evidence and safety concerns
Loop and mini gastric bypass — evidence and safety concerns:
ANY of the following
Loop/mini gastric bypass procedures have limited high‑quality evidence (primarily case series) and raise concerns about bile reflux and marginal ulceration; many surgeons favor Roux‑en‑Y modifications to reduce reflux risk. These techniques are generally considered investigational or used with caution pending robust comparative trials.
inv-13: Laparoscopic adjustable gastric banding (LASGB) — evidence and outcomes
Laparoscopic adjustable gastric banding (LASGB) — evidence and outcomes:
ANY of the following
LASGB has documented sustained weight loss in many patients but generally less than RYGB and with higher rates of reoperation and device‑related complications (slippage, erosion, need for replacement). CMS and other assessments have supported LASGB in selected patients but long‑term revision rates should be considered.
inv-14: Intragastric balloon (IGB) — efficacy and safety
Intragastric balloon (IGB) — efficacy and safety summary:
ANY of the following
Randomized trials show IGBs can increase short‑term weight loss versus diet alone, but weight regain commonly occurs after removal; FDA has approved specific IGB systems with limited indications and recommended removal at specified durations (typically 6 months). Serious adverse events including rare deaths have been reported and safety surveillance continues.
Systematic reviews indicate moderate improvements in metabolic parameters with IGBs but limited long‑term durability and potential for serious adverse events (gastric perforation, obstruction).
inv-15: StomaphyX (endoluminal plication) — evidence
StomaphyX (endoluminal plication) — evidence:
ANY of the following
Limited evidence from small case series and one prematurely terminated randomized trial indicates StomaphyX did not meet predefined efficacy endpoints for revisional therapy; current evidence is insufficient to support routine use.
inv-16: Bariatric surgery and fertility/pregnancy — professional guidance
Bariatric surgery and fertility/pregnancy — guidance:
ANY of the following
Professional guidance (ACOG) states bariatric surgery should not be considered as a treatment for infertility. Pregnancy after bariatric surgery requires appropriate counseling and timing considerations to optimize maternal and fetal outcomes.
inv-17: Bariatric surgery for idiopathic intracranial hypertension — evidence
Bariatric surgery for idiopathic intracranial hypertension (IIH) — evidence:
ANY of the following
Case series and small observational studies suggest improvement or resolution of IIH symptoms and papilledema after bariatric surgery in many patients, but evidence is limited (Class IV) and prospective controlled studies are needed before surgery is recommended solely for IIH outside established obesity criteria.
inv-18: Evidence summaries — evidence and outcomes described
Evidence summaries and selected clinical trial context:
ANY of the following
Randomized trials and observational studies demonstrate bariatric surgery (RYGB, sleeve, BPD/DS) is superior to medical/lifestyle therapy for weight loss and type 2 diabetes remission in appropriately selected patients, including some lower‑BMI patients in metabolic surgery trials; however, long‑term 'hard' outcomes and durability in lower‑BMI populations require further study.
Systematic reviews indicate procedures that include malabsorptive components (BPD/DS) yield greater weight loss and diabetes remission but with higher nutritional risks; restrictive procedures yield less weight loss but fewer metabolic complications. Professional consensus statements (e.g., DSS‑II, ASMBS) have updated consideration of metabolic surgery thresholds for T2DM where evidence supports benefit in selected lower‑BMI patients, with ethnicity‑specific BMI adjustments (−2.5 kg/m2 for Asian patients).
inv-19: COVERAGE CRITERIA — surgery for T2DM guidance and BMI/control-based thresholds
Coverage guidance for surgery for type 2 diabetes mellitus (T2DM):
ALL of the following
Bariatric/metabolic surgery may be considered for treatment of T2DM in patients meeting established obesity surgery criteria (BMI ≥35 kg/m2 with inadequately controlled hyperglycemia) and, in selected cases, for patients with BMI 30.0–34.9 kg/m2 when hyperglycemia is inadequately controlled despite optimal medical therapy, consistent with international consensus statements and specialty guideline recommendations; ethnicity‑specific BMI adjustments apply (reduce thresholds by 2.5 kg/m2 for Asian patients).
Patient selection should consider glycemic control, duration of diabetes, comorbidity profile, and the risks/benefits of surgery with requirement for lifelong follow‑up and monitoring for nutritional deficiencies.
inv-20: Endoluminal revisions and suturing devices — evidence summary
Endoluminal revisions and suturing devices — evidence summary:
ANY of the following
Transoral outlet reduction (TORe) using endoscopic suturing devices has randomized sham‑controlled evidence showing modest but significant short‑term weight loss/stabilization after RYGB with dilated GJA; results are procedure‑ and device‑dependent and longer‑term durability is under investigation.
Endoscopic suturing and plication techniques (ESG, endoscopic sleeve gastroplasty, OverStitch, ROSE, StomaphyX) show promising early results in small studies/series but lack large randomized long‑term comparative data; some devices have limited or failed trials.
inv-21: Other procedures and devices — evidence summaries
Other procedures and devices — evidence summaries:
ANY of the following
VBLOC (vagal nerve blocking) has mixed trial results; FDA approved indications are narrow and evidence for broad use is insufficient. Endoscopic liners (EndoBarrier) showed short‑term weight loss but device complications and explantation limited adoption. AspireAssist has FDA approval for specific indications with demonstrated weight loss but requires careful patient selection due to contraindications and potential device‑related complications.
inv-22: Evidence summaries — clinical findings and trial context
Selected clinical findings and trial context for endoscopic and surgical innovations:
ANY of the following
Emerging procedures (ESG, endoscopic sleeve gastroplasty, SADI‑S, SIPS, mini procedures) show varied short‑term weight loss and comorbidity improvements in cohort studies and early trials; many societies recommend cautious adoption and collection of outcomes through registries and high‑quality trials to establish long‑term safety and effectiveness.
inv-23: Evidence summaries and device indications — study findings and FDA approvals
Device approvals and study summaries (selected):
ANY of the following
FDA approvals (e.g., ReShape Dual Balloon, Orbera, AspireAssist, Maestro VBLOC) do not alone constitute broad coverage; payer coverage decisions consider trial evidence, safety signals (including post‑market reports), indications, and clinical benefit versus alternatives.
inv-24: Coverage criteria for conversion of SG to RYGB — Covered when ALL of the following are met
Coverage for conversion of sleeve gastrectomy to RYGB specifically for GERD:
ALL of the following
Conversion of sleeve gastrectomy to Roux‑en‑Y gastric bypass is considered medically necessary for treatment of symptomatic GERD when: (1) reflux is documented by abnormal 24‑hour pH monitoring or endoscopically proven esophagitis performed after the sleeve gastrectomy; and (2) symptoms persist despite optimal medical therapy including behavioral modification and at least one month of maximum PPI therapy.
When performed primarily for treatment of reflux that meets these criteria, conversion is not considered repeat bariatric surgery for coverage purposes.
inv-25: Coverage stance for SILSG — Covered when ALL criteria met (single-incision procedures)
Single‑incision laparoscopic sleeve gastrectomy (SILSG) — coverage stance:
ANY of the following
SILSG is considered investigational/experimental when performed to achieve outcomes beyond those of conventional multi‑port laparoscopic sleeve gastrectomy due to limited evidence; available series suggest feasibility but RCTs are lacking to demonstrate superiority or equivalent safety in routine practice.
inv-26: Coverage stance for prophylactic mesh — statements re: prophylactic mesh placement
Prophylactic mesh placement for prevention of incisional hernia — stance:
ANY of the following
Routine prophylactic mesh placement at closure after open bariatric surgery is considered investigational due to insufficient high‑quality evidence; some meta‑analyses suggest reduced incisional hernia risk but further high‑quality studies (including laparoscopic contexts) and cost‑utility analyses are needed.
inv-27: Coverage considerations for SADI-S/SIPS/SADIS/SADS-p — coverage considerations
Coverage considerations for SADI‑S/SIPS/SADIS/SADS‑p:
ANY of the following
SADI‑S/SIPS and other single‑anastomosis duodeno‑ileal procedures are increasingly reported with promising weight loss and diabetes outcomes but long‑term data and standardized technique reporting are limited. These procedures may be considered in the context of clinical protocols or in experienced centers with registry reporting and long‑term follow‑up, and adoption should follow ASMBS guidance emphasizing cautious implementation and nutritional monitoring.
inv-28: Society position and evidence caveats — evidence and society recommendations
Society positions and evidence caveats:
ANY of the following
Professional societies (ASMBS, AACE, DSS‑II) provide evolving guidance recognizing metabolic benefits of bariatric procedures for T2DM and endorsing certain newer procedures with caution; they emphasize requirement for long‑term outcome data, registry reporting, and center expertise.
inv-29: Clinical evidence synthesis — summary of selected clinical evidence
Clinical evidence synthesis highlights:
ANY of the following
High‑quality randomized trials demonstrate superiority of bariatric/metabolic surgery over medical therapy for T2DM remission and glycemic control in selected patients; observational data support reductions in macrovascular events and durable weight loss for many procedures but comparative safety profiles and long‑term outcomes vary by procedure type.
inv-30: Background evidence summaries — evidence without explicit coverage rules in this segment
Background evidence summaries — selected narrative synthesis (no explicit coverage rules in this segment):
ANY of the following
The NIH Consensus (1998) and multidisciplinary task groups have informed candidate selection emphasizing prior medical therapy failure, documentation of BMI thresholds and comorbidities, and preoperative commitment to long‑term follow‑up. Intensive multicomponent behavioral interventions are recommended preoperatively (commonly ≥12 sessions) to assess commitment and promote pre‑surgical weight loss goals (eg, 5–10% or 10% as initial target).
Noninvasive testing for NAFLD/NASH (FIB‑4, NFS, transient elastography, MRE, serum biomarker panels) is useful to screen for advanced fibrosis; liver biopsy remains gold standard but is recommended selectively rather than routinely during bariatric surgery absent clinical indicators of liver disease.
Endoscopic bariatric therapies and revisional endoscopic procedures (TORe, ESG, OverStitch) are promising minimally invasive options for management of weight regain or as primary therapies in selected patients, but long‑term durability and comparative effectiveness versus surgical approaches remain under study; society guidance recommends registry reporting and further RCTs.